GO:0050815 phosphoserine residue binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050815 phosphoserine residue binding is a molecular function describing the selective, non-covalent interaction of a protein module with a phosphorylated serine residue within another protein.
• Phosphoserine recognition is mediated by dedicated modular domains such as 14-3-3, FHA, BRCT, WW, MH2, and the SPOC domain, which decode serine phosphorylation signals into downstream cellular responses.
• The interaction is not simple electrostatic complementarity: acidic residues in partner proteins do not always mimic phosphoserine, and some modules such as TEX264 achieve high-affinity binding to LC3/GABARAP through mechanisms distinct from phosphomimicry.
• Phosphoserine-binding modules are central to signal transduction, cell-cycle control, DNA damage repair, transcription, and autophagy, making them high-value targets for mechanistic and drug-discovery research.
• Dysregulated phosphoserine recognition contributes to cancer, neurodegeneration, and developmental disorders, and pseudophosphatases such as MK-STYX illustrate how loss of catalytic and binding functions can alter signaling.
• CRISPR knockout, point-mutation, knock-in, and overexpression models combined with phosphoproteomics and structural biology are the core toolkit for dissecting phosphoserine residue binding in cells.
Description
Phosphoserine residue binding (GO:0050815) is the molecular function of selectively and non-covalently interacting with a serine residue that has been phosphorylated within a protein. Serine phosphorylation is one of the most abundant post-translational modifications in eukaryotic cells, and the ability to read this mark is essential for converting kinase activity into specific biological outcomes. Phosphoserine-binding modules act as decoders that recruit effector proteins, scaffold complexes, and regulate enzyme activity in a phosphorylation-dependent manner. The functional importance of this GO term spans nearly every major signaling axis. Phosphoserine/threonine-binding domains were recognized early as conserved modules that mediate inducible protein-protein interactions, and their structural and biochemical logic has been reviewed extensively. More recently, the SPOC domain was characterized as a phosphoserine-binding module that bridges transcription machinery with co- and post-transcriptional regulators, expanding the known repertoire of phosphoserine readers. Structural studies of phosphoserine aminotransferase have also revealed how a defined binding pocket coordinates L-phosphoserine, providing atomic-level insight into phosphoserine recognition. For researchers, GO:0050815 matters because it defines a mechanistic interface that can be perturbed genetically and pharmacologically. Mutating the phosphoserine acceptor site, the reader domain, or the kinase that deposits the mark can rewire signaling, and such perturbations are now routinely modeled with CRISPR-based approaches. Understanding phosphoserine residue binding therefore connects structural biology, cell signaling, disease mechanism, and therapeutic targeting.
phosphoserine residue binding At A Glance
| GO ID | GO:0050815 |
|---|---|
| GO term | phosphoserine residue binding |
| Ontology | molecular_function |
| Synonym | phosphoserine binding |
| Definition | Binding to a phosphorylated serine residue within a protein. |
| Major function | Decoding serine phosphorylation signals into protein-protein interactions, complex assembly, and downstream signaling. |
| Representative reader domains | 14-3-3, FHA, BRCT, WW, MH2, SPOC |
| Substrate context | Phosphoserine embedded in a protein, often within a short linear motif |
| Related modification | Serine phosphorylation deposited by serine/threonine kinases |
| Research relevance | Central to signal transduction, cell-cycle control, DNA repair, transcription, and autophagy |
What Is GO:0050815?
In our own words, GO:0050815 phosphoserine residue binding describes the ability of a protein or protein domain to recognize and bind a phosphorylated serine residue that is present within a protein substrate. The interaction is non-covalent and depends on the phosphate group and surrounding peptide context of the phosphoserine, rather than on free phosphoserine as a small molecule. This function is typically executed by modular domains such as 14-3-3, FHA, BRCT, WW, MH2, and SPOC, which use conserved pockets to engage the phosphoserine and flanking residues. The QuickGO synonym phosphoserine binding captures the same concept, and the term is classified under molecular_function because it describes a binding activity rather than a process or location.
Why Is phosphoserine residue binding Important in Cell Biology?
Phosphoserine residue binding is important because it is the principal mechanism by which cells convert serine phosphorylation into specific, reversible protein-protein interactions. Without phosphoserine readers, kinase signals would remain uninterpreted, and processes such as cell-cycle progression, DNA damage repair, transcriptional control, and autophagy would lose critical regulatory inputs. Because the interaction is modular and mutation-sensitive, it is also highly tractable for experimental dissection and for therapeutic intervention.
• Provides a general mechanism for decoding serine phosphorylation signals into biological outcomes.
• Controls inducible protein-protein interactions that regulate cell-cycle progression and checkpoint responses.
• Links transcription machinery to co- and post-transcriptional regulators through the SPOC domain.
• Contributes to DNA damage signaling and repair through FHA and BRCT phosphoserine recognition.
• Regulates autophagy and selective reticulophagy through phosphoserine-independent and phosphoserine-related interactions with LC3/GABARAP.
• Is dysregulated in cancer, neurodegeneration, and developmental disorders.
• Provides structural targets for small-molecule and peptide inhibitors of phosphoserine reader domains.
• Enables synthetic biology approaches that rewire signaling by adding or removing phosphoserine-binding modules.
• Supports biomarker discovery through phosphoproteomic mapping of reader-domain interactomes.
• Is essential for understanding pseudophosphatase and pseudokinase biology, where binding function can be uncoupled from catalysis.
Molecular Mechanism of phosphoserine residue binding
Recognition of the phosphoserine mark
In simple terms: The reader protein has a pocket that fits the phosphate group on serine, like a lock recognizing a key.
Phosphoserine residue binding begins with recognition of the phosphorylated serine side chain by a dedicated binding pocket. Structural and biochemical studies of phosphoserine/threonine-binding domains established that these modules use conserved residues to coordinate the phosphate group and to discriminate phosphoserine from phosphothreonine or unmodified serine. The FHA domain, for example, is a phosphothreonine-specific module whose structural logic has been reviewed in detail, illustrating how reader domains achieve phospho-amino-acid specificity. In phosphoserine aminotransferase, crystallographic analysis revealed the structural basis of L-phosphoserine binding, showing how a defined pocket accommodates the phosphorylated amino acid.
Context-dependent binding and motif selection
In simple terms: The reader does not just see the phosphate; it also reads the surrounding sequence, so context matters.
Phosphoserine residue binding is context-dependent: the affinity and specificity of a reader domain depend on residues flanking the phosphoserine, which form a short linear motif. This context dependence explains why not all phosphoserines are recognized equally and why acidic residues in a partner protein do not always mimic phosphorylation. For instance, the reticulophagy receptor TEX264 binds LC3/GABARAP with high affinity through a mechanism in which acidic residues do not simply mimic phosphorylation, highlighting the importance of local sequence and structural context in phosphoserine-related recognition.
Domain architecture and modularity
In simple terms: Many phosphoserine readers are modular, meaning the binding domain can be plugged into different proteins.
Phosphoserine-binding activity is often carried by compact, independently folding domains that can be exchanged between proteins. Classic examples include 14-3-3, FHA, BRCT, WW, and MH2 domains, which are found in diverse signaling and regulatory proteins. The SPOC domain is a more recently defined phosphoserine-binding module that bridges transcription machinery with co- and post-transcriptional regulators, demonstrating that new phosphoserine reader folds continue to be discovered. This modularity allows a single phosphoserine mark to be interpreted by different effectors in different cellular contexts.
Coupling to downstream signaling and complexes
In simple terms: Once the reader binds, it can recruit other proteins or change the activity of a complex.
Binding of a phosphoserine reader to its target typically nucleates the assembly of a larger protein complex or alters the activity of the bound protein. In transcription, the SPOC domain links transcription machinery to co- and post-transcriptional regulators, thereby coupling serine phosphorylation to gene expression programs. In signal transduction, phosphoserine/threonine-binding domains mediate inducible interactions that propagate kinase signals to downstream effectors. Serine phosphorylation of STAT proteins illustrates how this modification can control transcription factor function, providing a physiological context in which phosphoserine recognition operates.
Regulation and specificity checkpoints
In simple terms: The cell controls when and where binding happens through kinases, phosphatases, and competing interactions.
Phosphoserine residue binding is regulated by the opposing activities of kinases and phosphatases, which deposit and remove the phosphoserine mark, and by the availability and post-translational modification of the reader domain itself. Pseudophosphatases such as MK-STYX illustrate how a catalytically inactive phosphatase can retain regulatory roles in signaling, underscoring that binding and catalysis can be uncoupled. Specificity is further enforced by the local sequence context, by competition among reader domains, and by the structural constraints of the binding pocket.
Key Genes Involved in GO:0050815 phosphoserine residue binding
The following genes and proteins represent major phosphoserine-binding modules and related regulators that are commonly studied in the context of GO:0050815.
| Gene | Major Role | Research Relevance |
|---|---|---|
| YWHAB | 14-3-3 beta; phosphoserine/threonine-binding adaptor | Model for phosphoserine-dependent protein-protein interactions |
| YWHAG | 14-3-3 gamma; phosphoserine/threonine-binding adaptor | Regulates signaling and cell-cycle checkpoints |
| SFMBT1 | SPOC domain-containing protein | Links transcription machinery to co- and post-transcriptional regulators |
| PHF3 | SPOC domain-containing transcription regulator | Phosphoserine-binding module in transcription |
| PSAT1 | Phosphoserine aminotransferase | Structural model for L-phosphoserine binding |
| STAT1 | Signal transducer and activator of transcription | Serine phosphorylation regulates transcriptional activity |
| STAT3 | Signal transducer and activator of transcription | Serine phosphorylation regulates transcriptional activity |
| TEX264 | Reticulophagy receptor | High-affinity LC3/GABARAP binding; context-dependent phosphoserine-related recognition |
| STYX | Pseudophosphatase MK-STYX | Uncoupled binding and catalytic functions in signaling |
| RAD53 | Checkpoint kinase (yeast model) | FHA domain phosphothreonine/phosphoserine signaling |
| MDC1 | Mediator of DNA damage checkpoint | BRCT/FHA phosphoserine recognition in DNA repair |
| BRCA1 | DNA repair and checkpoint protein | BRCT domain phosphoserine binding |
| TP53 | Tumor suppressor | Phosphoserine-dependent regulation by kinases |
| AKT1 | Serine/threonine kinase | Deposits phosphoserine marks read by 14-3-3 proteins |
| MAPK1 | Mitogen-activated protein kinase | Serine/threonine phosphorylation of substrates |
| CDK1 | Cyclin-dependent kinase | Cell-cycle phosphoserine signaling |
| ATM | DNA damage kinase | Phosphoserine signaling in DNA damage response |
How Is phosphoserine residue binding Regulated?
Phosphoserine residue binding is regulated at multiple levels. The abundance of the phosphoserine mark itself is controlled by the balance between serine/threonine kinases and phosphatases, so any change in kinase or phosphatase activity alters the availability of binding sites. Reader-domain availability is regulated by expression, localization, and post-translational modification of the reader protein. Competition among reader domains for the same phosphoserine site can determine which downstream pathway is activated, and the local sequence context around the phosphoserine sets the affinity and specificity of the interaction. In addition, pseudophosphatases and catalytically inactive signaling proteins can modulate phosphoserine-dependent complexes without removing the phosphate mark, as illustrated by MK-STYX.
phosphoserine residue binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| STAT3 | Cancer; transcriptional dysregulation | Point mutation of serine phosphorylation site; KO in cancer cell lines |
| BRCA1 | Hereditary breast and ovarian cancer; DNA repair deficiency | Knock-in of BRCT domain mutations; KO for DNA damage assays |
| PHF3 | Transcriptional dysregulation | KO and tagged knock-in for interaction proteomics |
| TEX264 | Autophagy and reticulophagy dysfunction | KO and point mutation of LC3/GABARAP-binding interface |
| STYX | Signaling dysregulation | Overexpression and KO to dissect pseudophosphatase function |
Cancer
Dysregulated serine phosphorylation and phosphoserine recognition are common in cancer. Serine phosphorylation of STAT proteins controls transcriptional programs that drive proliferation and survival, and aberrant kinase activity can create or destroy phosphoserine-binding sites on oncoproteins and tumor suppressors. Phosphoserine reader domains such as BRCT and FHA are central to DNA damage signaling, and their dysfunction contributes to genomic instability and cancer predisposition. Because phosphoserine-binding interfaces are modular and structurally defined, they are attractive targets for therapeutic intervention.
Neurodegeneration
Altered serine phosphorylation and phosphoserine-dependent protein interactions have been implicated in neurodegenerative processes, where disrupted signaling complexes can impair neuronal survival and proteostasis. The context-dependent nature of phosphoserine recognition means that mutations affecting either the phosphoserine site or the reader domain can have profound effects on neuronal signaling. Pseudophosphatases such as MK-STYX further illustrate how uncoupling binding from catalysis can perturb signaling pathways relevant to neuronal function.
Developmental and transcriptional disorders
Phosphoserine-binding modules that bridge transcription machinery with co- and post-transcriptional regulators, such as the SPOC domain, are directly linked to gene expression control. Disruption of these interactions can alter developmental gene programs and contribute to transcriptional disorders. Studying phosphoserine residue binding in this context helps explain how signaling inputs are converted into changes in gene expression.
From phosphoserine residue binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a phosphoserine reader alter signaling output? | CRISPR knockout of the reader gene followed by phosphoproteomics and pathway analysis |
| Is a specific serine phosphorylation site required for binding? | Point mutation of the serine to alanine or glutamate (phosphomimetic) |
| Can a disease-associated reader mutation be corrected? | Knock-in of wild-type or mutant reader domain for rescue experiments |
| Where does the reader bind in cells? | Tagged knock-in with fluorescent or affinity tags for imaging and interactomics |
| Does overexpression of a reader domain sequester its targets? | Overexpression of wild-type or binding-deficient reader constructs |
| Which phosphoserine sites are recognized in a disease context? | CRISPR library screening combined with phosphoproteomic profiling |
How to Study the phosphoserine residue binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phosphoproteomics | Global serine phosphorylation sites | Mapping signaling changes after CRISPR perturbation |
| Affinity purification mass spectrometry | Protein interaction partners of reader domains | Defining phosphoserine-dependent interactomes |
| X-ray crystallography | Atomic structure of reader-phosphoserine complexes | Understanding binding pocket specificity |
| Isothermal titration calorimetry | Binding affinity and thermodynamics | Quantifying reader-phosphopeptide interactions |
| Fluorescence polarization | Binding affinity in solution | Screening reader domain specificity |
| Live-cell imaging | Localization and dynamics of tagged readers | Visualizing phosphoserine-dependent recruitment |
| CRISPR knockout | Loss-of-function phenotype | Testing requirement for a reader gene |
| CRISPR knock-in | Tagged or mutant reader expression | Rescue and interaction studies |
Phosphoproteomics and interaction proteomics
Mass spectrometry-based phosphoproteomics maps serine phosphorylation sites globally, while affinity purification of reader domains followed by mass spectrometry identifies the proteins they bind. These approaches are essential for defining the interactome of phosphoserine-binding modules and for detecting changes caused by CRISPR perturbations.
Structural biology
X-ray crystallography, NMR, and cryo-electron microscopy reveal how phosphoserine-binding pockets coordinate the phosphate group and discriminate among phospho-amino acids. Structural studies of phosphoserine aminotransferase and FHA domains provide templates for understanding phosphoserine recognition at atomic resolution.
Cell-based binding assays
Pull-down assays, fluorescence polarization, isothermal titration calorimetry, and surface plasmon resonance measure the affinity and specificity of phosphoserine reader domains for their targets. These assays are often combined with point mutations of the phosphoserine site or the reader pocket to test causality.
Functional genomics and imaging
CRISPR knockout and knock-in models, combined with live-cell imaging of tagged readers, allow researchers to test how phosphoserine residue binding affects signaling dynamics, complex assembly, and cellular phenotypes. Transcriptomic and proteomic readouts then connect binding events to downstream gene expression and pathway changes.
How CRISPR Can Be Used to Study GO:0050815 phosphoserine residue binding
Knockout
CRISPR knockout of a phosphoserine reader gene eliminates the binding function and reveals its contribution to signaling, transcription, or DNA repair. For example, knocking out a SPOC domain-containing protein can disrupt the bridge between transcription machinery and co- and post-transcriptional regulators, providing a clean loss-of-function background for rescue experiments. Knockout of pseudophosphatases such as MK-STYX can also reveal non-catalytic signaling roles.
Point Mutation
Point mutation of the serine phosphorylation site to alanine prevents phosphoserine formation, while mutation to glutamate or aspartate is often used as a phosphomimetic. However, acidic residues do not always mimic phosphorylation, as shown for TEX264 binding to LC3/GABARAP, so phosphomimetic mutations must be validated experimentally. Point mutations in the reader domain itself can also abolish phosphoserine binding while preserving protein stability.
Knock-in
Knock-in of tagged or mutant reader domains allows precise tracking of phosphoserine-dependent interactions in a physiological context. Tagged knock-in of SPOC domain proteins enables interactome and imaging studies without overexpression artifacts. Knock-in of disease-associated mutations in BRCT or FHA domains can model how altered phosphoserine recognition contributes to disease.
Overexpression
Overexpression of wild-type or binding-deficient reader domains can sequester phosphoserine targets and act as a dominant-negative perturbation. This approach is useful for testing whether a reader domain is sufficient to drive a phenotype and for comparing wild-type versus binding-deficient constructs. Overexpression should be interpreted carefully because it can create non-physiological interactions.
How EDITGENE Supports phosphoserine residue binding Research
Researchers studying phosphoserine residue binding-related genes often need to determine whether a candidate gene is causally involved in a signaling, transcriptional, or disease phenotype. EDITGENE provides end-to-end CRISPR cell model generation and screening services that allow precise perturbation of phosphoserine readers, writers, and erasers in relevant cell backgrounds.
Contact EDITGENE today to design your custom CRISPR model for phosphoserine residue binding research.
Frequently Asked Questions About phosphoserine residue binding
What is phosphoserine residue binding?
Phosphoserine residue binding (GO:0050815) is the molecular function of selectively and non-covalently binding to a phosphorylated serine residue within a protein, typically through dedicated reader domains such as 14-3-3, FHA, BRCT, WW, MH2, and SPOC.
What genes are involved in phosphoserine residue binding?
Genes encoding phosphoserine reader domains include YWHAB and YWHAG (14-3-3 proteins), SFMBT1 and PHF3 (SPOC domain proteins), BRCA1 and MDC1 (BRCT/FHA proteins), and PSAT1, which binds L-phosphoserine.
What is the GO ID for phosphoserine residue binding?
The Gene Ontology ID for phosphoserine residue binding is GO:0050815, classified under the molecular_function aspect.
How does phosphoserine binding differ from phosphothreonine binding?
Phosphoserine and phosphothreonine binding are related but distinct: some domains, such as the FHA domain, are phosphothreonine-specific, while others recognize phosphoserine or both, and specificity is determined by the structure of the binding pocket.
Why is phosphoserine residue binding important in cancer?
Dysregulated serine phosphorylation and phosphoserine recognition affect DNA repair, transcription, and proliferation pathways, and reader-domain dysfunction can contribute to genomic instability and cancer progression.
Can acidic residues mimic phosphoserine?
Not always. Acidic residues do not always mimic phosphorylation, as shown by the high-affinity binding of TEX264 to LC3/GABARAP, so phosphomimetic mutations must be validated experimentally.
What methods are used to study phosphoserine residue binding?
Common methods include phosphoproteomics, affinity purification mass spectrometry, X-ray crystallography, isothermal titration calorimetry, fluorescence polarization, live-cell imaging, and CRISPR-based perturbation.
What is the SPOC domain?
The SPOC domain is a phosphoserine-binding module that bridges transcription machinery with co- and post-transcriptional regulators, expanding the known set of phosphoserine readers.
How do pseudophosphatases relate to phosphoserine binding?
Pseudophosphatases such as MK-STYX lack catalytic activity but can still regulate signaling, illustrating that binding and catalytic functions can be uncoupled in phosphoserine-related pathways.
How can CRISPR help study phosphoserine residue binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to remove, modify, tag, or amplify phosphoserine readers and their substrates, enabling causal tests of binding function in cells.
Conclusion
Phosphoserine residue binding (GO:0050815) is a central molecular function that converts serine phosphorylation into specific protein-protein interactions and downstream cellular responses. Its mechanisms are executed by modular reader domains such as 14-3-3, FHA, BRCT, WW, MH2, and SPOC, whose specificity depends on the phosphate group and the surrounding sequence context. Understanding this function is essential for cancer, neurodegeneration, and transcriptional regulation research, and it is highly amenable to CRISPR-based perturbation and modern proteomic and structural methods. By combining knockout, point-mutation, knock-in, overexpression, and library-screening approaches, researchers can dissect how individual phosphoserine sites and reader domains contribute to disease-relevant phenotypes. EDITGENE supports these efforts with validated cell model generation and bioinformatics tailored to phosphoserine residue binding research.
References
- 1. Yaffe MB et al.. 2001. Phosphoserine/threonine-binding domains.. Curr Opin Cell Biol 13(2):131-8 PMID: 11248545
- 2. Appel LM et al.. 2023. The SPOC domain is a phosphoserine binding module that bridges transcription machinery with co- and post-transcriptional regulators.. Nat Commun 14(1):166 PMID: 36631525
- 3. Battula P et al.. 2013. Structural basis of L-phosphoserine binding to Bacillus alcalophilus phosphoserine aminotransferase.. Acta Crystallogr D Biol Crystallogr 69(Pt 5):804-11 PMID: 23633589
- 4. Yaffe MB et al.. 2001. PhosphoSerine/threonine binding domains: you can't pSERious?. Structure 9(3):R33-8 PMID: 11286893
- 5. Decker T et al.. 2000. Serine phosphorylation of STATs.. Oncogene 19(21):2628-37 PMID: 10851062
- 6. Popelka H et al.. 2022. When acidic residues do not mimic phosphorylation: high-affinity binding of the reticulophagy receptor TEX264 to LC3/GABARAP.. Autophagy 18(11):2515-2518 PMID: 36041015
- 7. Hinton SD. 2020. Pseudophosphatase MK-STYX: the atypical member of the MAP kinase phosphatases.. FEBS J 287(19):4221-4231 PMID: 32472731
- 8. Mahajan A et al.. 2008. Structure and function of the phosphothreonine-specific FHA domain.. Sci Signal 1(51):re12 PMID: 19109241
